There are currently 100 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and Ontario.
Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma
NCT04365556
Recruiting
To test the preliminary efficacy of the TASC adherence promotion intervention for adolescents with asthma in a feasibility randomized controlled trial compared to treatment as usual control arm.
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
09/12/2023
Locations: Cincinnati Children's Medical Hospital, Cincinnati, Ohio
Conditions: Asthma
Register for Updates
Personalized Environment and Genes Study
NCT00341237
Recruiting
Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influe... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
05/02/2024
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Diabetes, Heart Disease, Asthma
Register for Updates
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
NCT01143480
Recruiting
Background: - Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers. Objectives: - To examine how specific genes and proteins in blood cells respond to environmental e... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/02/2024
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Register for Updates
Sample Collections From the Airways of Asthmatic Patients
NCT00001888
Recruiting
Fiberoptic bronchoscopy is a procedure which involves passing a pencil-thin tube into the lung in order to collect fluid and cells from the airways. Fiberoptic bronchoscopy can collect cells from the walls of airways by gently brushing them (bronchial brushing). In addition, squirting small amounts of sterile water in to the airway and gently suctioning it back into the bronchoscope (bronchoalveolar lavage) collects cells. In this study, researchers plan to perform these tests on patients with... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/02/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Asthma
Register for Updates
The Dallas Asthma Brain and Cognition (ABC) Study
NCT03794856
Recruiting
Asthma is a chronic inflammatory airway disease that leads to episodic symptom exacerbations, which exerts a substantial burden on quality of life and can influence other health domains if not adequately controlled. Asthma prevalence rates have increased in the past decade, affecting 8.4% (25.7 million people) of the United States population. The economic costs of asthma have been estimated annually with $56 billion in the US alone. Despite progress in pharmacological treatment, overall asthma c... Read More
Gender:
All
Ages:
Between 40 years and 69 years
Trial Updated:
05/01/2024
Locations: Southern Methodist University, Dallas, Texas +1 locations
Conditions: Asthma
Register for Updates
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/29/2024
Locations: GSK Investigational Site, Birmingham, Alabama +439 locations
Conditions: Asthma
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/29/2024
Locations: Teva Investigational Site 15581, Paradise Valley, Arizona +96 locations
Conditions: Asthma
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
All
Ages:
Between 6 years and 18 years
Trial Updated:
04/26/2024
Locations: Research Site, Mobile, Alabama +80 locations
Conditions: Asthma
Register for Updates
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
NCT05202262
Recruiting
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
04/26/2024
Locations: Research Site, Saraland, Alabama +182 locations
Conditions: Asthma
Register for Updates
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
NCT05755906
Recruiting
This is a 12-week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler relative to budesonide metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
04/26/2024
Locations: Research Site, Chandler, Arizona +140 locations
Conditions: Asthma
Register for Updates
Evaluate Pharmacokinetics and Safety of Slow Release DHEA
NCT05623059
Recruiting
This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with severe asthma.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
04/25/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana +1 locations
Conditions: Asthma, Genotype
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2024
Locations: Research Site, Birmingham, Alabama +133 locations
Conditions: Asthma
Register for Updates